Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation
- PMID: 16573707
- DOI: 10.1111/j.1365-2605.2006.00689.x
Phosphodiesterase 5 inhibitors in the treatment of premature ejaculation
Abstract
To date, there is no FDA-approved therapy for premature ejaculation (PE). Recently, phosphodiesterase 5 inhibitors (PDE5-Is) have been demonstrated to have encouraging results in the treatment of PE by a few studies. The aim of this review was to assess the updated manuscripts and thereafter present the practical recommendations and possible mechanisms concerning PDE5-Is for treating PE. Using MEDLINE, we searched and assessed the peer manuscripts published from 1 January 1996 to 1 September 2005 about PDE5-Is for treating PE. The results show that the number of patients in all the reports is very few and most of the studies do not employ double-blinded and placebo-controlled tests, though they are prospective and randomized. Therefore, the results and conclusions might be biased. PDE5-Is are suggested to be used in PE with old age or associated with erectile dysfunction (ED), or to be employed alone or in combination with selective-serotonin reuptake inhibitors (SSRIs) when SSRIs fail to treat PE; behavioural therapy is proposed to be used for preventing the recurrence of PE following withdrawal of PDE5-Is. In addition, for the PE patient with a definite aetiological cause, the aetiology should be cured first, if PE still exists, followed by PDE-Is prescription. Possible mechanisms that are involved include relaxing the smooth muscles of vas deferens, seminal vesicle, prostate and urethra; decreasing the central sympathetic output; inducing peripheral analgesia; prolonging the duration of erection; and increasing confidence, the perception of ejaculatory control, overall sexual satisfaction, and decreasing the post-orgasmic refractory time to achieve a second erection after ejaculation. Well-designed multicentre studies are urgently warranted to further elucidate the efficacies and safety as well as mechanisms of PDE5-Is in the treatment of PE.
Similar articles
-
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study.BJU Int. 2011 Apr;107(8):1274-7. doi: 10.1111/j.1464-410X.2010.09646.x. Epub 2010 Sep 7. BJU Int. 2011. PMID: 21929518 Clinical Trial.
-
The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data.Eur Urol. 2007 Nov;52(5):1331-9. doi: 10.1016/j.eururo.2007.08.005. Epub 2007 Aug 17. Eur Urol. 2007. PMID: 17728050 Review.
-
PDE-5 inhibitors: current status and future trends.Urol Clin North Am. 2005 Nov;32(4):511-25, viii. doi: 10.1016/j.ucl.2005.08.012. Urol Clin North Am. 2005. PMID: 16291042 Review.
-
Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.Urology. 2006 Oct;68(4):689-96. doi: 10.1016/j.urology.2006.05.009. Urology. 2006. PMID: 17070333 Review. No abstract available.
-
Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.J Sex Med. 2004 Nov;1(3):322-36. doi: 10.1111/j.1743-6109.04047.x. J Sex Med. 2004. PMID: 16422964 Review.
Cited by
-
Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity.Nat Rev Urol. 2021 Feb;18(2):115-127. doi: 10.1038/s41585-020-00417-1. Epub 2021 Jan 13. Nat Rev Urol. 2021. PMID: 33442049 Review.
-
Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.Nephrourol Mon. 2016 Jan 27;8(1):e32286. doi: 10.5812/numonthly.32286. eCollection 2016 Jan. Nephrourol Mon. 2016. PMID: 26981497 Free PMC article.
-
Premature ejaculation: do we have effective therapy?Transl Androl Urol. 2013 Mar;2(1):45-53. doi: 10.3978/j.issn.2223-4683.2013.01.02. Transl Androl Urol. 2013. PMID: 26816723 Free PMC article. Review.
-
The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.Cent European J Urol. 2014;67(3):314-8. doi: 10.5173/ceju.2014.03.art20. Epub 2014 Aug 18. Cent European J Urol. 2014. PMID: 25247094 Free PMC article. Review.
-
New insights on premature ejaculation: a review of definition, classification, prevalence and treatment.Asian J Androl. 2012 Nov;14(6):822-9. doi: 10.1038/aja.2012.108. Epub 2012 Oct 15. Asian J Androl. 2012. PMID: 23064688 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical